The abstract is read at the publisher; the summary is JClub's.
RECIST’s current relevance is limited as solid-tumor cancer therapeutics have evolved beyond cytotoxic chemotherapy in how treatment outcomes are assessed.
- Why it matters: As cancer treatments shift, the field needs outcome measures that better reflect meaningful patient benefit rather than relying on older response criteria.
- What they did: This Viewpoint reviews how Response Evaluation Criteria in Solid Tumors (RECIST) fit—or fail to fit—modern therapeutic goals, given the move away from cytotoxic chemotherapy.
- The result: The discussion implies RECIST may not adequately capture patient-relevant outcomes in today’s solid-tumor treatment landscape, motivating more appropriate assessment approaches.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.